tbuckley/cabot-search huggingface dataset:
School attendance in childhood cancer survivors.
Authors: A. E. French, E. Tsangaris, S. Guger, M. Barrera, R. Brown, S. Urbach, D. Stephens, P. C. Nathan
Journal: Journal of Clinical Oncology (2011)

9581 Background: Although school absenteeism is expected in children undergoing cancer therapy, little is known about school attendance in childhood cancer survivors (CCS). Methods: We approached consecutive CCS (≥8 years) attending the Hospital for Sick Children’s AfterCare Clinic and obtained absenteeism rates for CCS and their closest in age sibling (if available) using school report cards for the 2008-09 academic year. Absenteeism was compared to a population control group of 167,752 students in the Toronto District School Board (TDSB). The Child Vulnerability Scale and the Pediatric Quality of Life Inventory (PedsQL) were administered. CCS’ treatment was assigned an intensity score (1-4) using the Intensity of Treatment Rating Scale 2.0. One sample t-tests and nonparametric tests were used to compare absenteeism rates. Univariate and multiple regression analyses were used to assess variables associated with days absent. Results: A total of 131 CCS (median age 13.4 years; range 8.0-19.2) at a median of 9.4 years (range 4.3-17.3) from diagnosis, along with 78 siblings (median age 13 years; range 7-18) participated. CCS and their siblings missed significantly more school than the TDSB control population (mean±SD: 11.0±9.4 and 9.9±9.8 vs. 5.0±5.6 days, for both, p<0.0001). There was no difference in absenteeism between matched CCS-sibling pairs (11.1±9.9 vs. 9.9±9.8 days, p=0.38). Absenteeism in CCS was significantly associated with higher treatment intensity (p=0.01) and diagnosis (p=0.03). Brain tumor CCS missed more school than solid tumor or leukemia/lymphoma CCS (mean±SD: 18.6±3.1 vs. 12.7±1.6 vs. 10.5±2.0 days). Older age at study and a low PedsQL Physical Health Summary Score (HSS) were associated with increased absenteeism, but did not reach statistical significance (for both, p=0.08). Parent’s perception of their child’s vulnerability (p=0.55) and a low PedsQL Psychosocial HSS (p =0.23) were not associated with absenteeism. Conclusions: CCS and their siblings miss more school than the general population. Brain tumor survivors and those with more intense therapy are at most risk. Care givers, educators and health care providers must work to minimize school absenteeism in CCS.
Allocating Organs to Cognitively Impaired Patients
Authors: Scott D. Halpern, David Goldberg
Journal: New England Journal of Medicine (2017)

Interview with Dr. Scott Halpern on whether cognitive function should be considered in decisions about organ allocation. (08:08)Download Should patients’ cognitive function be weighed in the allocation of organs? This debate raises important questions, from the ethics of making judgments regarding others’ quality of life to the science of cognitive impairment’s effect on post-transplantation survival.
Interferon Gamma (IFNγ) Interferes with the Effects of Tyrosine Kinase Inhibitors (TKI) In CML Cells.
Authors: Stefanie AE Held, Anita Bringmann, Annkristin Heine, Grethe Kock, Ruth-Miriam Körber, Nina Manon Seltmann, Peter Brossart
Journal: Blood (2010)
A Distributed International Patient Data Registry for Hairy Cell Leukemia
Authors: Leslie A. Andritsos, Michael R. Grever, Mirela Anghelina, Claire E Dearden, Monica Else, James S. Blachly, Omkar Lele, Farhad Ravandi, Clive S Zent, James B. Johnston, Versha Banerji, Francesco Forconi, Anthony D. Ho, Thorsten Zenz, Sascha Dietrich, Judit Demeter, Jacqueline C. Barrientos, Jan A. Burger, Timothy G. Call, Nicholas Chiorazzi, Daniel J. DeAngelo, Julio Delgado, Andrei Fagarasanu, Brunangelo Falini, Alessandro Gozzetti, Jeffrey Jones, Gunnar Juliusson, Eric H. Kraut, Robert J. Kreitman, Loree Larratt, Francesco Lauria, Gerard Lozanski, Emili Montserrat, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme R. Quest, Kanti R. Rai, Tadeusz Robak, Alan Saven, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Enrico Tiacci, Xavier Troussard, Omar Abdel-Wahab, Pier Luigi Zinzani, Christopher Heckler, Philip R.O. Payne
Journal: Blood (2016)
Pemetrexed as first or second line in 112 danish patients.
Authors: Vasiliki Panou, Ida Nielsen, Jens Benn Soerensen, Oluf D. Roe
Journal: Journal of Clinical Oncology (2016)

e20084 Background: A phase III study on Malignat Pleural Mesothelioma (MPM) by Vogelzang et al. (2003) established pemetrexed-cisplatin as standard therapy. The aim of this study is to evaluate the current standard MPM chemotherapy in light of the previous regimens and to identify significant factors that influence survival. Methods: Patients with histologically verified MPM, treated with chemotherapy during 2003-2013 were retrieved from medical records of Aalborg University Hospital, Denmark. The patients were treated with pemetrexed (PEM) first-line from 2008; before that other types (OTHER) of chemotherapy were given, mostly carboplatin-vinorelbin. Survival time, age at diagnosis, sex, TNM staging, epithelioid or non-epithelioid subtype, comorbidities, WHO performance status (PS) and total number of chemotherapy cycles (CC) were analyzed with multivariate Cox regression analysis (MCRA) and Kaplan-Meier (KM) to investigate their correlation with survival. Results: A total of 112 MPM patients underwent chemotherapy (PEM=60, OTHER=52, Table). Among the PEM, 57% got vinorelbine, while 61% of OTHER received pemetrexed in second line. KM demonstrated no difference in survival between PEM and OTHER (median 14 vs 13 months, p=0.96). MCRA showed that high number of CC (p=1.74x10-9), age (p=0.0002), first-line treatment with PEM (p=0.004) and absence of comorbidities (p=0.04) had a significant positive influence on MPM survival. Conclusions: Literature acknowledges that pemetrexed first-line treatment, age, and comorbidities influence MPM survival, as seen in our results. Number of CC was the most significant factor in MCRA but could be flawed by the fact that patients without tumor progression or side effects were able to be on treatment longer. Maintenance chemotherapy is not the current standard for MPM but it might be speculated whether such treatment may increase survival. Further research is needed to clarify these points. First-line PEM OTHER Survival months, median (p=0.96) 14 13 Age years, median 69 63 TNM median 3 2 Gender male:female 54:6 48:4 Comorbidities yes:no 7:53 14:38 WHO PS median 1 1 Cycles median (range) 8 (1-25) 7 (1-18) Subtype (epithelioid:non- epithelioid) 32:28 23:29 Second-line most used vinorelbine pemetrexed
Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.
Authors: Roberto Latagliata, Massimo Breccia, Ida Carmosino, Chiara Sarlo, Rosa De Cuia, Marco Mancini, Francesca Biondo, Eleonora Russo, Annalisa De Vellis, Daniela Diverio, Franco Mandelli, Giuliana Alimena
Journal: Blood (2004)
A Woman in Her 60s With Chronic Meningitis
Authors: Michael R. Pichler, Joseph E. Parisi, James P. Klaas
Journal: JAMA Neurology (2017)

A renal transplant recipient in her 60s presented with a history of chronic headaches and progressive encephalopathy. Serial cerebrospinal fluid examinations were consistent with chronic lymphocytic meningitis, but no definitive cause was identified. Imaging studies showed the development of an enhancing suprasellar mass lesion and hydrocephalus. Symptoms progressed despite empiric antimicrobial therapy, and the patient died after an acute large-volume subarachnoid hemorrhage. A complete autopsy was performed. The differential diagnosis, pathologic findings, and diagnosis are discussed.
Second Allogeneic Stem Cell Transplantation for Hematologic Malignancies Using Chemotherapy Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa
Authors: Barbara Spitzer, Miguel-Angel Perales, Nancy A. Kernan, Susan E. Prockop, Nicholas Webb, Hugo Castro-Malaspina, Esperanza B Papadopoulos, James W. Young, Andromachi Scaradavou, Rachel Kobos, Sergio Giralt, Richard J O'Reilly, Farid Boulad
Journal: Blood (2014)
Differences in Expression Patterns of DNMTs and TSG Proteins in Lymphoid Tissue Section Play an Important Role in Their Association
Authors: Lobna Alkebsi, Hiroshi Handa, Kenichi Tahara, Hiroaki Shimizu, Takuma Ishizaki, Kunio Yanagisawa, Saitoh Takayuki, Tetsuhiro Kasamatsu, Makiko Takizawa, Hirokazu Murakami
Journal: Blood (2015)
Inhibition of KLF5–Myo9b–RhoA Pathway–Mediated Podosome Formation in Macrophages Ameliorates Abdominal Aortic Aneurysm
Authors: Dong Ma, Bin Zheng, Toru Suzuki, Ruonan Zhang, Chunyang Jiang, Disi Bai, Weina Yin, Zhan Yang, Xinhua Zhang, Lianguo Hou, Hong Zhan, Jin-kun Wen
Journal: Circulation Research (2017)

Abdominal aortic aneurysms (AAAs) are characterized by pathological remodeling of the aortic wall. Although both increased Krüppel-like factor 5 (KLF5) expression and macrophage infiltration have been implicated in vascular remodeling, the role of KLF5 in macrophage infiltration and AAA formation remains unclear.To determine the role of KLF5 in AAA formation and macrophage infiltration into AAAs.KLF5 expression was significantly increased in human AAA tissues and in 2 mouse models of experimental AAA. Moreover, in myeloid-specific Klf5 knockout mice (myeKlf5-/- mice), macrophage infiltration, medial smooth muscle cell loss, elastin degradation, and AAA formation were markedly decreased. In cell migration and time-lapse imaging analyses, the migration of murine myeKlf5-/- macrophages was impaired, and in luciferase reporter assays, KLF5 activated Myo9b (myosin IXB) transcription by direct binding to the Myo9b promoter. In subsequent coimmunostaining studies, Myo9b was colocalized with filamentous actin, cortactin, vinculin, and Tks5 in the podosomes of phorbol 12,13-dibutyrate-treated macrophages, indicating that Myo9b participates in podosome formation. Gain- and loss-of-function experiments showed that KLF5 promoted podosome formation in macrophages by upregulating Myo9b expression. Furthermore, RhoA-GTP levels increased after KLF5 knockdown in macrophages, suggesting that KLF5 lies upstream of RhoA signaling. Finally, Myo9b expression was increased in human AAA tissues, located in macrophages, and positively correlated with AAA size.These data are the first to indicate that KLF5-dependent regulation of Myo9b/RhoA is required for podosome formation and macrophage migration during AAA formation, warranting consideration of the KLF5-Myo9b-RhoA pathway as a therapeutic target for AAA treatment.
Decitabine (DAC) Treatment Induces Very Early In Vivo DNA Methylation and Transcriptome Changes in Primary AML Peripheral Blood Blasts
Authors: Rainer Claus, Dietmar Pfeifer, Maika Almstedt, Björn Hackanson, Manuela Zucknick, Christoph Plass, Michael Lübbert
Journal: Blood (2011)
STEM-03ATRACURIUM BESYLATE AND OTHER NEUROMUSCULAR BLOCKING AGENTS PROMOTE ASTROGLIAL DIFFERENTIATION AND DEPLETE GLIOBLASTOMA STEM CELLS
Authors: Raffella Spina, Dillon Voss, Andrew Sloan, Eli Bar
Journal: Neuro-Oncology (2015)

Glioblastoma multiforme (GBM) are the most common primary malignant brain tumor in adults, with a median survival of about one year. This poor prognosis is attributed primarily to therapeutic resistance and tumor recurrence after surgical removal, with the root cause suggested to be found in glioblastoma stem cells (GSCs). Using glial fibrillary acidic protein (GFAP) and microtubule associated protein-2 (MAP-2) as reporters of astrocytic and neuronal differentiation, respectably; we isolated multiple clones from three independent patient-derived GSC neurosphere lines which express GFAP or MAP2 in a remarkably stable fashion. We next show that elevated expression of GFAP is associated with reduced clonogenicity in vitro and tumorigenicity in vivo. Utilizing this in vitro cell-based differentiation reporter system we next screened the NIH clinical collection libraries for agents capable of inducing GSC astrocytic differentiation. We identified the non-depolarizing neuromuscular blocker, Atracurium Besylate, as a small molecule which effectively induces astroglial but not neuronal differentiation of GSC. Functionally, Atracurium Besylate treatment significantly inhibited the clonogenic capacity of several independent patient-derived GSC neurosphere lines, a phenomenon which was largely irreversible. Vecuronium, another non-depolarizing neuromuscular blocker, also induced GSC astrocytic differentiation suggesting that inhibition of acetylcholine receptors (AChRs) may be the mechanism responsible for GSC astrocytic differentiation. To investigate the clinical importance of AChRs in gliomas, we examined clinical outcomes and found that glioma patients with tumors overexpressing CHRNA1 or CHRNA9 (encoding for the AChR-α1 or AChR-α9 subunits) exhibit significant shorter overall survival. Finally, we found that ex-vivo pre-treatment of GSCs with Atracurium Besylate significantly increased the survival of mice xenotransplanted with these cells, therefore suggesting that tumor initiating subpopulations have been reduced.
Actual (ABW) or Ideal (IBW) Body Weight to Calculate CD34+ Cell Dose in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Myeloma?
Authors: J. Krishnamurthy, V. Singh, O. Frankfurt, Andrew M Evens, J. Altman, L. Gordon, S. Singhal, M. Tallman, S. Williams, J. Winter, J. Mehta
Journal: Blood (2008)
Human Cytomegalovirus Tegument Protein UL82 Inhibits STING-Mediated Signaling to Evade Antiviral Immunity
Authors: Yu-Zhi Fu, Shan Su, Yi-Qun Gao, Pei-Pei Wang, Zhe-Fu Huang, Ming-Ming Hu, Wei-Wei Luo, Shu Li, Min-Hua Luo, Yan-Yi Wang, Hong-Bing Shu
Journal: Cell Host & Microbe (2017)
Expansion of Bone Marrow (BM) Progenitors and Mobilization of Multilineage Progenitor Cells Associated with Once Per Cycle Administration of Long-Acting Growth Factors Neulasta and Aranesp with Chemotherapy (CT): Biology and Nature of Response.
Authors: Saroj Vadhan-Raj, Carlos E. Bueso-Ramos, G. Hangoc, K. Christopherson, M. Collard, H.E. Broxmeyer
Journal: Blood (2004)
Chrom3D: three-dimensional genome modeling from Hi-C and nuclear lamin-genome contacts
Authors: Jonas Paulsen, Monika Sekelja, Anja R. Oldenburg, Alice Barateau, Nolwenn Briand, Erwan Delbarre, Akshay Shah, Anita L. Sørensen, Corinne Vigouroux, Brigitte Buendia, Philippe Collas
Journal: Genome biology (2017)

Current three-dimensional (3D) genome modeling platforms are limited by their inability to account for radial placement of loci in the nucleus. We present Chrom3D, a user-friendly whole-genome 3D computational modeling framework that simulates positions of topologically-associated domains (TADs) relative to each other and to the nuclear periphery. Chrom3D integrates chromosome conformation capture (Hi-C) and lamin-associated domain (LAD) datasets to generate structure ensembles that recapitulate radial distributions of TADs detected in single cells. Chrom3D reveals unexpected spatial features of LAD regulation in cells from patients with a laminopathy-causing lamin mutation. Chrom3D is freely available on github.
Intranasal azelastine (2 sprays/nostril twice daily) vs intranasal fluticasone propionate (2 sprays/nostril once daily) for the treatment of patients with seasonal allergic rhinitis over a 14-day period
Authors: W Carr, P Ratner, Claus Bachert, P Lieberman, E Meltzer, U Munzel, D Price
Journal: Allergy (2012)
Association Between Infant Mortality Attributable to Birth Defects and Payment Source for Delivery — United States, 2011–2013
Authors: Lynn M. Almli, Caroline C. Alter, Rebecca B. Russell, Sarah C. Tinker, Penelope P. Howards, Janet Cragan, Emily Petersen, Gerard E. Carrino, Jennita Reefhuis
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Birth defects are a leading cause of infant mortality in the United States (1), accounting for approximately 20% of infant deaths. The rate of infant mortality attributable to birth defects (IMBD) in the United States in 2014 was 11.9 per 10,000 live births (1). Rates of IMBD differ by race/ethnicity (2), age group at death (2), and gestational age at birth (3). Insurance type is associated with survival among infants with congenital heart defects (CHD) (4). In 2003, a checkbox indicating principal payment source for delivery was added to the U.S. standard birth certificate (5). To assess IMBD by payment source for delivery, CDC analyzed linked U.S. birth/infant death data for 2011-2013 from states that adopted the 2003 revision of the birth certificate. The results indicated that IMBD rates for preterm (<37 weeks of gestation) and term (≥37 weeks) infants whose deliveries were covered by Medicaid were higher during the neonatal (<28 days) and postneonatal (≥28 days to <1 year) periods compared with infants whose deliveries were covered by private insurance. Similar differences in postneonatal mortality were observed for the three most common categories of birth defects listed as a cause of death: central nervous system (CNS) defects, CHD, and chromosomal abnormalities. Strategies to ensure quality of care and access to care might reduce the difference between deliveries covered by Medicaid and those covered by private insurance.
Depletion and Restoration of the Intravascular Nitrite (NO2-) Reserve Modulate Susceptibility to Liver Vaso-Occlusive Infarction in Sickle Cell Transgenic Mice.
Authors: Lewis L. Hsu, Sruti Shiva, Audrey Noguchi, Erin Curtis, Peter MacArthur, Nicolaas J.H. Raat, Bhalchandra A. Diwan, Alan N. Schechter, Constance Tom Noguchi, Mark T. Gladwin
Journal: Blood (2007)
Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo
Authors: Kerstin Maria Kampa-Schittenhelm, Hans-Joerg Buehring, Michael Bonin, Wichard Vogel, Lothar Kanz, Thomas Haverkamp, Marcus M Schittenhelm
Journal: Blood (2015)
Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,
Authors: Rebecca Elstrom, John P. Leonard, Stanley J. Goldsmith, Paul Christos, Peter Martin, Joseph Osborne, Daniel Lebovic, Ramsey Abdallah, June Greenberg, Richard R. Furman, Jia Ruan, Kent A. Griffith, Morton Coleman, Mark S. Kaminski
Journal: Blood (2011)
Nodal disease in the setting of metastatic renal cell carcionoma: Can a lymph node dissection alter outcomes?
Authors: Brian Francis Chapin, Scott Edward Delacroix, Patrick Aloysius Kenney, Graciela M Nogueras Gonzalez, Pheroze Tamboli, Eric Jonasch, Nizar M. Tannir, Christopher G. Wood
Journal: Journal of Clinical Oncology (2012)

386 Background: The impact of lymph node dissection (LND) in patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN) is unclear. The aims of this study were to determine the predictive ability of LN status for overall survival (OS) in patients treated with CN in the targeted therapy era and if LND increases the morbidity of CN. Methods: We performed a retrospective review of all patients with mRCC treated with CN at a single institution between 2004–2010. Patients participating in open or unpublished trials were excluded, leaving 173 patients for analysis. LNs &gt;1cm by long axis diameter were considered clinically positive (cN+). OS was calculated using COX proportional hazard regression. Complications were classified using the modified Clavien system. Results: Sixty-five (37.6%) patients were clinically node positive (cN+). Median OS was significantly worse for the cN+ patients compared to cN0 patients [17.5 vs 29.1 mos;HR 1.8;(1.3-2.6)]. Clinical node status remained an independent predictor of OS on multivarible analysis (MV) [HR 1.7;CI 1.1-2.7]. LND was performed in 61/65 (93.4%) cN+ patients and in 56/108 (52%) of cN0 patients. Pathologic node positive disease (pN+) was more common in cN+ compared to cN0 patients (75% vs. 23%,p &lt;0.001). pN+ patients had worse median OS than pN0 patients [16.0 v 35.5 mos;HR 2.3(1.5-3.6)]. Among pN+ patients (n=54), complete resection of all identifiable nodal disease was associated with an improved OS compared to patients with unresectable nodal disease (n=4) [16.0 v 5.6 mos;HR 2.9(1.0-8.3)]. On univariate analysis LND patients were more likely to have a post-operative complication (64% vs 43%,p=0.008) and more specifically chylous ascites (12 v 0,p=0.01). Despite this association, LND did not reach statistical significance when MV analysis was performed [OR 1.9;(0.9-3.8)]. Conclusions: Among patients undergoing CN, those with cN+ disease had worse OS. Likewise, pN+ patients have worse OS than pN0 patients. LND is associated with higher morbidity than CN alone. Further efforts are needed to determine removal of pathologic nodes alters the natural history of the disease, and if the benefit offsets the increased morbidity.
Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia,
Authors: Alfonso Quintás-Cardama, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Mark Brandt, Sherry Pierce, Gautam Borthakur, Jorge E. Cortes
Journal: Blood (2011)
Response rate with weekly epirubicin and docetaxel as neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer (BC)
Authors: S.-C. Chen, H.-K. Chang, Y.-C. Lin, W.-M. Leung, J. T. Chang, Y.-C. Cheung, S. Hsueh, Y.-F. Lo, H.-P. Tsai, M.-F. Chen
Journal: Journal of Clinical Oncology (2005)

885 Background: In a previous phase II study of patients (pts) with locally-advanced BC, we showed that NAC with epirubicin (E) 35mg/m2 and paclitaxel 80mg/m2 administered on days 1 and 8 every 3 wks, resulted in a high clinical complete response (cCR) rate and a pathological complete response (pCR) rate of 11.4%, with acceptable toxicity (Proc. ASCO, 2003; abst. 231). Methods: Pts with large (>4cm) tumors were treated with E 45 mg/m2 and docetaxel (D) 35mg/m2, both days 1 and 8, every 3 wks for 3 cycles before BC surgery. No prophylactic G-CSF or antibiotics were allowed. All pts had surgery 3 wks after NAC. Following surgery, pts were treated with 6 cycles of CEF (cyclophosphamide 500mg/m2, E 70 mg/m2, 5-fluorouracil 500mg/m2, q3 wks) Results: A total of 42 pts were enrolled between 2003 and 2004; 32 are evaluable. Median age was 47 years (range, 26–69), 63% of pts were estrogen receptor negative, and 28% overexpressed HER-2/neu. Mean tumor size before NAC was 6.5cm. After NAC, mean tumor size decreased to 2.1cm and 12 pts (38%) had negative axillary lymph nodes. Four pts had breast-conserving surgery (BCS), although 10 were candidates for BCS on clinical evaluation. The cCR and clinical partial response rates were 41% and 50%, respectively, and no pts had disease progression. A pCR was found in 7 pts (22%) including 3 with focal intraductal carcinoma only. Grade 3–4 leukopenia was reported in 3 pts (9%) and one pt developed febrile neutropenia. Nonhematologic toxicities included grade 1–2 nausea and vomiting in 28 (88%) and 5 (16 %) pts, respectively, and grade 1–2 arthralgia and grade 2 alopecia in 13 pts (41%).Conclusions: Neoadjuvant chemotherapy with 3 cycles of E 45mg/m2 and D 35mg/m2 (days 1 and 8, every 3 wks) is feasible with acceptable toxicity for most pts, resulting in a pCR rate of 22%. No significant financial relationships to disclose.